PLX Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Protalix Biotherapeutics Inc

Watchlist Manager

Watchlist

Price: 2.1 USD 3.45% Market Closed

Market Cap: $169.2m

P	Protalix Biotherapeutics Inc AMEX:PLX	US
	Insight Enterprises Inc NASDAQ:NSIT	US
	Alliance Entertainment Holding Corp NASDAQ:AENT	US

Profitability Summary

Protalix Biotherapeutics Inc's profitability score is 39/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin

49%

Strong 3Y Average Gross Margin

55%

Declining Gross Margin

60% > 49%

Negative Operating Margin

-10%

Low 3Y Average Operating Margin

Operating Margin is Increasing

-33% > -10%

Negative Net Margin

-13%

Low 3Y Average Net Margin

Net Margin is Increasing

-38% > -13%

Negative Free Cash Flow Margin

-26%

Negative 3Y Average Free Cash Flow Margin

-5%

Free Cash Flow Margin is Increasing

-55% > -26%

Negative ROE

-14%

Positive 3Y Average ROE

View All

Hide

Collapse

39 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.